岳岳欲试
Lv5
1020 积分
2024-01-28 加入
-
First-line treatment for advanced NSCLC in older patients and those with poor performance status
22天前
已完结
-
A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial
1个月前
已完结
-
PFS, OS or toxicity: What is the most important factor in the treatment of EGFR-mutated lung cancer?
1个月前
已关闭
-
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial
2个月前
已关闭
-
非小细胞肺癌新辅助治疗疗效病理评估专家共识
3个月前
已完结
-
New promises and challenges in the treatment of advanced non-small-cell lung cancer
3个月前
已完结
-
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
3个月前
已完结
-
enaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
3个月前
已完结
-
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study
3个月前
已完结
-
Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study
5个月前
已完结